CD20 Protein-VLP (AA 1-297) (Biotin)

Catalog No. ABIN7448157

Product Details

Target: CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))

Protein Type: VLP

Biological Activity: Active

Protein Characteristics: AA 1-297

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This CD20 protein is labelled with Biotin.

Application: Immunogen (Imm), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)

Purpose: Biotinylated Human CD20 Protein-VLP

Sequence: Met1-Pro297

Characteristics: Recombinant Biotinylated Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297.

Purity: > 95 % as determined by HPLC

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1EU per μg by the LAL method.

Biological Activity Comment: The affinity constant of 0.68 nM as determined in SPR assay (Biacore T200).

Application Details

Application Notes:

• Antibody Discovery: Immunization, Screening, Functional Characterization
• Affinity determination: ELISA, SPR
• In vivo pharmacokinetic analysis
• CMC method development
• CAR-T Positive Rate Detection
• Blood sample determination: ELISA

Comment:

Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in PBS ( pH 7.4).

Storage: -80 °C

Storage Comment: Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))

Alternative Name: CD20 (MS4A1 Products)

Synonyms: B1 Protein, Bp35 Protein, CD20 Protein, CVID5 Protein, LEU-16 Protein, MS4A2 Protein, S7 Protein, AA960661 Protein, Cd20 Protein, Ly-44 Protein, Ms4a2 Protein, MS4A1 Protein, bp35 Protein, cd20 Protein, ms4a2 Protein, leu-16 Protein, ms4a4c Protein, cd20-like Protein, membrane spanning 4-domains A1 Protein, membrane-spanning 4-domains, subfamily A, member 1 Protein, B-lymphocyte antigen CD20 Protein, MS4A1 Protein, Ms4a1 Protein, ms4a1 Protein, LOC101694281 Protein

Background: B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

Molecular Weight: 34.3 kDa.